Protocol showed to be inappropriate for the evaluation of the selected patients

To provide evidence based prospectives of the potential benefit effects of paricalcitol, an analog of vitamin D, over the prevention / retardation of the progression of neoangiogenesis (vessels), atherosclerosis and vascular calcification.

Providing prospective results based on evidence of potential beneficial effects of paricalcitol, an analogue of vitamin D in the prevention / delay of progression of neoangiogenesis (vessels), atherosclerosis and vascular calcification.

Inclusion Criteria:

• Patients aged between 50 and 75 years.
• Chronic kidney disease stage 5 D or 4-5 No D as calculated glomerular filtration rate (MDRD).
• Concentration of intact parathyroid hormone (iPTH): 150-400 pg/ml.
• Plasma concentrations of 25 (OH) vitamin D <30 ng/ml.
• Without vitamin D supplementation for 3 months before the study.
• Serum P> 3.8 mg / dl.
• Serum Ca> 9.8 mg / dl.
• No history of cardiovascular events (angina or myocardial infarction, stroke, peripheral arterial disease).
• No exclusion criteria for the use of contrast.

Exclusion Criteria:

• Allergic reaction to sulfur hexafluoride.
• Recent unstable cardiac symptoms.
• Patients with recent coronary intervention (<7 days)
• Patients with class III and IV heart failure or severe arrhythmias.
• Severe pulmonary hypertension.